{"id":44878,"date":"2023-12-29T11:05:00","date_gmt":"2023-12-29T10:05:00","guid":{"rendered":"https:\/\/www.stille.se\/us\/mfn_news\/report-from-the-extraordinary-general-meeting-of-stille-ab-on-december-29-2023\/"},"modified":"2024-02-23T11:53:45","modified_gmt":"2024-02-23T10:53:45","slug":"report-from-the-extraordinary-general-meeting-of-stille-ab-on-december-29-2023","status":"publish","type":"mfn_news","link":"https:\/\/www.stille.se\/us\/news\/report-from-the-extraordinary-general-meeting-of-stille-ab-on-december-29-2023\/","title":{"rendered":"Report from the extraordinary general meeting of Stille AB on December 29, 2023"},"content":{"rendered":"
Stille AB held an extraordinary general meeting on Friday, December 29, 2023. The main resolutions passed at the meeting were as follows. More detailed information about the contents of the resolutions may be obtained from the complete notice of the extraordinary general meeting and the complete proposals, which are available on the company\u2019s website, www.stille.se.<\/strong><\/div>\n

Resolution on the number of board members, election of a board member and resolution on board remuneration<\/span><\/h3>\n

The meeting resolved, in accordance with the shareholder Linc AB\u2019s proposal, that the board of directors shall consist of six board members with no deputies. Furthermore, the meeting resolved to elect Victor Steien as new ordinary member of the board of directors and that Victor Steien shall receive SEK 135,000 in annual remuneration, adjusted for the service time as a member of the board of directors of the company.<\/span><\/p>\n

The resolutions are contingent on, and will enter into force in connection with, Impilo Surgical Products AB taking possession of the newly issued share, see below.<\/span><\/p>\n

Resolution on an amendment of the articles of association<\/span><\/h3>\n

The meeting resolved, in accordance with the board of directors' proposal, to adopt new articles of association, as a result of, among other things, the directed issue of shares, see below. Through the adoption of the new articles of association, alterations have been made to the share limits, from a minimum of 2,000,000 and a maximum of 8,000,000 to a minimum of 6,700,000 and a maximum of 26,800,000. Simultaneously, adjustments to the share capital limits have been made, from a minimum of SEK 10,000,000 and a maximum of SEK 40,000,000 to a minimum of SEK 33,000,000 and a maximum of SEK 132,000,000.<\/span><\/p>\n

Resolution on approval of the board of directors' resolution on a directed issue of shares<\/span><\/h3>\n

The meeting resolved, in accordance with the board of directors' proposal, to approve the board of directors' resolution from November 29, 2023, on a directed issue of shares mainly in accordance with the following.<\/span><\/p>\n

The directed share issue shall consist of an issue of a maximum of 3,971,963 shares, whereby the company's share capital is increased by not more than SEK 19,859,815. The subscription price per share is SEK 107 per share. The right to subscribe for new shares shall, with deviation from the shareholders pre-emption rights, solely belong to Linc AB, Lannebo Fonder, SEB Investment Management, ShapeQ, Aktia Fund Management Company Ltd, Healthinvest Partners AB, Ramhill AB, Schroders, Odin Fonder, Impilo and Funds managed by Berenberg AM.<\/span>
\n\u00a0<\/p>\n

\n

For more information, please contact:\u00a0<\/span><\/span><\/p>\n

Board of Directors of Stille AB<\/strong>
\nEkbacken 11, SE-644 30 Torsh\u00e4lla<\/span><\/span>
\n+46 (0)8 588 580 00 | www.stille.se<\/span><\/span><\/span>
\n\u00a0<\/span><\/span><\/p>\n<\/div>\n

\n

Stille AB (publ) publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world\u2019s oldest medical device companies. Stille\u2019s main business areas are surgical instruments and c-arm tables. Stille\u2019s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym \u201cSTIL\u201d with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se.<\/span><\/span><\/p>\n<\/div>\n